Richard M. Stone, MD, on the SWOG S1117 Study
2014 ASH Annual MeetingRichard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “A Randomized Phase II Study of Azacitidine Combined With Lenalidomide or With Vorinostat vs Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117,” presented by Mikkael A. Sekeres, MD, MS.
Related Videos
Matthew Lunning, DO, on Ublituximab Plus TGR-1202 in Lymphoma
Matthew Lunning, DO, of the University of Nebraska Medical Center, on abstract 801, “Ublituxima...
Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289,
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 380,
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 6,
Hagop Kantarjian, MD, on CAR T Cells in Relapsed/Refractory ALL
Richard M. Stone, MD, on the SAL-SORAML Trial
James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinic...
